Israeli healthtech VC aMoon Velocity invests $6 million in Nectin Therapeutics
Summary
aMoon Velocity invested $6 million in Nectin Therapeutics as part of a financing round that is expected to reach $15 million. Integra Holdings also joined the round. Nectin Therapeutics develops monoclonal antibodies that target Nectin proteins to help immune systems fight cancer. The company says it is in advanced development stages for several antibody candidates and aims to strengthen immunotherapy options for cancer patients.
Funding
Amount
$6.0M
Total raised
Date
July 14, 2020
Announcement date
Investors
Hebrew University of Jerusalem, Integra Holdings
Lead investors
Company
-
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected